Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
NCT02587520
Completed
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US). Primary Objective * To describe the safety profile of each SP0173 investigational formulation. Observational Objective: * To describe the immunogenicity of each SP0173 investigational formulation.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/15/2022
Locations: Not set, Las Vegas, Nevada
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Register for Updates
A Phase 2 Study to Evaluate Immune Responses of FluMist®
NCT00461981
Completed
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Gender:
ALL
Ages:
Between 12 months and 35 months
Trial Updated:
09/10/2021
Locations: Henderson Pediatrics, Henderson, Nevada
Conditions: Influenza Vaccine
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: University Medical Center of Southern Nevada, Las Vegas, Nevada
Conditions: Staphylococcal Vaccine
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
NCT02117934
Completed
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/18/2019
Locations: Clinical Research Advantage, Inc., Henderson, Nevada +1 locations
Conditions: Healthy
Register for Updates
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
NCT00614614
Completed
The purpose of the study is to characterize the immunogenicity \& safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Henderson, Nevada
Conditions: Infections, Meningococcal
Register for Updates
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
NCT01204671
Completed
This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older. This study is also designed to assess the lot-to-lot consistency of vaccine GSK2321138A. The blinding will be double blind for all groups except for the GSK2604409A Group which will be open.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Las Vegas, Nevada
Conditions: Influenza
Register for Updates
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
NCT02285998
Completed
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/26/2017
Locations: Clinical Research Consortium-Nevada, Las Vegas, Nevada
Conditions: Influenza
Register for Updates
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
NCT01934127
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/04/2017
Locations: GSK Investigational Site, Las Vegas, Nevada
Conditions: Influenza
Register for Updates
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
NCT02214225
Completed
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2017
Locations: Site 298, Las Vegas, Nevada
Conditions: Influenza, Human
Register for Updates
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02117570
Completed
This study will investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. The study will assess the safety and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
12/05/2016
Locations: Clinical Research Center of Nevada, LLC, Las Vegas, Nevada
Conditions: Clostridium Difficile Associated Disease
Register for Updates
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
NCT00345683
Completed
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been up... Read More
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
10/18/2016
Locations: GSK Investigational Site, Las Vegas, Nevada
Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Register for Updates
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
NCT02124161
Completed
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have previously received 23-valent pneumococcal polysaccharide vaccine.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/23/2016
Locations: Clinical Research Center of Nevada, LLC, Las Vegas, Nevada +1 locations
Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Register for Updates